This book highlights recent developments of organic and inorganic nanomedicine that play a major role in anti-angiogenic cancer therapy. In addition, the authors present examples of nanomedicine based anti-angiogenic agents and their applications in cancer therapy. Angiogenesis is a pathophysiological phenomenon that modulates cell proliferation and cell migration and plays important roles in cancer. Anti-angiogenic nanotherapies have gained immense attention in recent times as alternative cost-effective therapies that opened a new dimension in cancer theranostics. Further the challenges of the anti-angiogenic nanotherapies and possible future perspective are detailed.

Provides an overview of angiogenesis and anti-angiogenesis and highlights anti-angiogenic drugs in cancer treatment Presents developments of organic and inorganic nanomedicine that play a major role in anti-angiogenic cancer therapy Includes an analysis of the limitations of nanomedicine and possible solutions that facilitate clinical translation

Autorentext

**Dr Sudip Mukherjee: Sudip Mukherjee, PhD, MRSC, is an assistant professor at the School of Biomedical Engineering at the Indian Institute of Technology, BHU (IIT BHU). Dr Mukherjee completed his PhD from CSIR-IICT, Hyderabad, India in 2017 followed by postdoctoral position at Rice University, USA in 2022. His present research interests include the development of advanced biomaterials for cell therapy and drug/gene delivery in diabetes, cancer theranostics, angiogenesis, and immunomodulatory applications. He is member of the Royal Society of Chemistry, UK and AACR, USA. He has published 67 publications, 5 books, 12 book chapters, 15 patents. He serves as an associate editor for the BMC Cancer and Frontiers in Chemistry. Dr. Vijay Sagar Madamsetty obtained his Ph.D. in chemical science from the Academy of Scientific and Innovative Research (AcSIR), India. With a fervent dedication to pioneering research in nanomedicine spanning 15 years, he embarked on his journey at the Council of Scientific and Industrial Research-Indian Institute of Chemical Technology (CSIR-IICT). Currently, he is a senior scientist at PolyaRNA Therapeutics in Cambridge, Massachusetts, USA. Dr. Madamsetty's career highlights include his tenure at CSL Seqirus, where he focused on the development of SamRNA-LNP-based nano vaccines targeting influenza diseases. Presently, his focus has shifted towards advancing mRNA-LNP-based vaccines and therapeutics. Dr. Rakesh C Reddy Meka is a Scientist, with over 15 years of academic & industrial research experience. Special expertise in Immunology, Cell and gene therapy, vaccine development and Nanotechnology. Experience in Cell based assay development techniques with substantial experience in cell and molecular biology, in-vitro, and in-vivo techniques. Involved in the COVID vaccine development project (COVAXIN) and CAR T therapy products. He published peer reviewed articles in RSC, Elsevier, and ACS publications. Lipi Pradhan is a research scholar presently pursuing her Ph.D. degree in the School of Biomedical Engineering, IIT BHU, Varanasi. She has earned her M.Sc. in Zoology from the Department of Zoology, Ranchi University. Her research interests involved designing cell-based therapy for treating rare genetic disorders and green synthesis of nanoparticles for various biomedical applications. Devyani Yenurkar is a Prime Minister's Research Fellow (PMRF) in the School of Biomedical Engineering at the Indian Institute of Technology IIT(BHU). She received her master’s degree in pharmacy (Pharmaceutics) from SNDT University, Mumbai. Her present interest in research includes work with nanomaterials for their potential applications in the field of blood anticoagulation and thrombosis. Sumit Manna completed his B.Sc. and M.Sc. in Human Physiology from the University of Calcutta, West Bengal. Currently, he is a research scholar pursuing his Ph.D. degree in the School of Biomedical Engineering at IIT (BHU), Varanasi. His research work focuses on the development of cell-based therapies for the treatment of genetic disorders. Durba Banerjee is currently pursuing her Ph.D. in School of Biomedical Engineering at IIT BHU Varanasi, where her research is dedicated to cell- based therapies for tissue regeneration and internal wound healing. She holds a Master’s a degree in Biotechnology, from Gautam Buddha University, Greater Noida

Inhalt
Chapter 1 - Introduction.- Chapter 2 - Current Anti-angiogenic Therapies and their Limitations.- Chapter 3 - Nanomedicine.- Chapter 4 - Organic Nanoparticles in Anti-angiogenic Cancer Therapy.- Chapter 5 - Inorganic Nanoparticles in Anti-angiogenic Cancer Therapy.- Chapter 6 - Potential Challenges in Anti-angiogenic Nanotherapies.- Chapter 7 - Conclusion.